Products Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) + DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)
Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) + DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) Phase 3 Completed 📈 Rising Tetanus, Diphtheria, Pertussis
Apr 1, 2007 → Dec 1, 2009
About Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) + DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis) + DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed) is a phase 3 stage product being developed by Sanofi for Tetanus. The current trial status is completed. This product is registered under clinical trial identifier NCT00467519. Target conditions include Tetanus, Diphtheria, Pertussis.
Clinical Trials (1) NCT ID Phase Status Start Completion Indication NCT00467519 Phase 3 Completed Apr 1, 2007 Dec 1, 2009 Tetanus
Product Company Stage Hype Score Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®) + Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®) Sanofi Approved Tetanus-diphtheria-acellular pertussis (Tdap) vaccine Sanofi Approved Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus + Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus Sanofi Phase 3 Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed + Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed Sanofi Approved DTaP-IPV/Hib Combined vaccine + DTaP-IPV vaccine and Hib vaccine + DTaP-IPV/Hib Combined vaccine Sanofi Phase 3 Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed + Diphtheria and Tetanus toxoids adsorbed Sanofi Phase 3 Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine + Tetanus and Diphtheria Toxoids Adsorbed For Adult Use Sanofi Approved Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1 + Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2 + Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3 + Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4 + Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed + Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Sanofi Phase 1/2 Investigational Tdap vaccine Formulation B + Investigational Tdap vaccine Formulation C + Investigational Tdap vaccine Formulation A + Investigational Tdap vaccine Formulation D + Licensed Tdap vaccine Sanofi Phase 1 Tetanus Immune Globulin (Human) + Diphtheria-Tetanus Toxoids Adsorbed Grifols Approved
Other Products from Sanofi